New York, May 28, 2024 - PRISM MarketView - Shares in biopharmaceutical company, CorMedix (Nasdaq: CRMD), rose in morning trading on Tuesday after the company announced that it has entered into a multi-year commercial supply contract with a top-tier dialysis provider for the supply of DefenCath® (taurolidine and heparin). DefenCath® is the first FDA-approved catheter lock solution (CLS) designed to reduce the incidence of catheter-related bloodstream infections in adults receiving chronic hemodialysis.
CorMedix received NDA approval of DefenCath® in November 2023, and began commercializing the product in the inpatient setting in April 2024. CorMedix expects to begin commercialization in outpatient dialysis clinics in July.
“I am pleased with the progress we are making in our discussions with outpatient dialysis providers, and solidifying this agreement ensures that potentially thousands of patients at risk for a catheter related bloodstream infection will have access to DefenCath. Utimately our goal is to ensure the broadest access possible to this important infection reduction mechanism.”
CorMedix CEO, Joseph Todisco
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and anticipates launch in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information, visit: www.cormedix.com.
About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to monitoring and analyzing small-cap stocks in emerging sectors. We offer up-to-the-minute financial news, provide comprehensive investment tools, and foster a dynamic community of investors. Central to our offerings are proprietary indices that track emerging sectors, including biotechnology, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or authorized broker-dealer or investment advisor and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
PRISM MarketView
646-863-6341
Prism MarketView | Stock Market News and Investment Opportunities
PRISM MarketView - Social Media (X)